Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2024

This “Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Proto oncogene protein c-akt inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Proto oncogene protein c-akt inhibitors Understanding

Proto oncogene protein c-akt inhibitors: Overview

Protein kinase B (PKB), also known as Akt, is the collective name of a set of three serine/threonine-specific protein kinases that play key roles in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration. There are three different genes that encode isoforms of Protein kinase B. These three genes are referred to as AKT1, AKT2, and AKT3 and encode the RAC alpha, beta, and gamma serine/threonine protein kinases respectively. Akt isoforms are overexpressed in a variety of human tumors, and, at the genomic level, are amplified in gastric adenocarcinomas (Akt1), ovarian (Akt2), pancreatic (Akt2) and breast (Akt2) cancers. The Akt kinases regulate cellular survival and metabolism by binding and regulating many downstream effectors, e.g. Nuclear Factor-?B, Bcl-2 family proteins, master lysosomal regulator TFEB and murine double minute 2 (MDM2).

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Proto oncogene protein c-akt inhibitors R&D. The therapies under development are focused on novel approaches for Proto oncogene protein c-akt inhibitors.

Proto oncogene protein c-akt inhibitors Emerging Drugs Chapters

This segment of the Proto oncogene protein c-akt inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Proto oncogene protein c-akt inhibitors Emerging Drugs

MK 2206: Merck MK-2206 is a drug candidate being investigated to help treat cancer. Its chemical formula is C25H21N5O. It acts as an allosteric AKT inhibitor. It is a highly selective inhibitor of pan-Akt, namely, of all three Akt isoforms Akt1, Akt2, and Akt3. Currently, it is in Phase III stage of clinical trial evaluation to treat variouscancers.

Ipatasertib: Genentech Ipatasertib is an oral, highly specific, investigational medicine designed to target and bind to all three isoforms of AKT, which blocks the PI3K/AKT signaling pathway and may prevent cancer cell growth and survival. Ipatasertib is being studied in tumors that are frequently found to have activation of the PI3K/AKT pathway, including breast and prostate cancers. Clinical studies are ongoing to evaluate the efficacy and safety of ipatasertib and the opportunity it may provide to address significant unmet needs for patients with these diseases. Currently, it is in Phase III stage of development to treat breast and prostatecancer.

Proto oncogene protein c-akt inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Proto oncogene protein c-akt inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Proto oncogene protein c-akt inhibitors

There are approx. 14+ key companies which are developing the Proto oncogene protein c-akt inhibitors. The companies which have their Proto oncogene protein c-akt inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Genentech.

Phases

This report covers around 14+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Proto oncogene protein c-akt inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Proto oncogene protein c-akt inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Proto oncogene protein c-akt inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto oncogene protein c-akt inhibitors drugs.

Proto oncogene protein c-akt inhibitors Report Insights

• Proto oncogene protein c-akt inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Proto oncogene protein c-akt inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Proto oncogene protein c-akt inhibitors drugs?
• How many Proto oncogene protein c-akt inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proto oncogene protein c-akt inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Proto oncogene protein c-akt inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Proto oncogene protein c-akt inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck
• Genentech
• Signpath Pharma
• Kazia Therapeutics
• HUYA Bioscience International
• AstraZeneca
• Novartis Oncology
• Aytu BioPharma
• CURACLE
• Almac Discovery
• Taiho Pharmaceutical
• Astex Pharmaceuticals
• Prescient Therapeutics
• Laekna Therapeutics
• Tactical Therapeutics

Key Products

• MK 2206
• Ipatasertib
• Curcumin liposomal
• Paxalisib
• Tucidinostat
• Capivasertib
• Miransertib
• Afuresertib
• Enzastaurin
• CU 05
• API-2
• Pravitinib
• Uprosertib
• ALM 301
• ARQ 751
• TAS 0612
• AT 13148

This product will be delivered within 2-4 business days.